Ligand Pharmaceuticals Hits New 52-Week High of $189.60

Ligand Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 189.60 on October 24, 2025. This achievement marks a remarkable 135.11% increase in the company's stock price over the past year, significantly outperforming the S&P 500, which has seen a gain of 16.9% during the same period.
As a small-cap player in the Pharmaceuticals & Biotechnology industry, Ligand Pharmaceuticals has a market capitalization of USD 3,250 million. Despite its recent stock performance, the company remains in a loss-making position, with a negative return on equity of -5.83%. The stock's price-to-book ratio stands at 3.92, indicating how the market values the company's equity relative to its book value.

Ligand's debt-to-equity ratio is reported at -0.29, reflecting a unique financial structure. The company does not offer a dividend yield, which is common among firms in growth phases within the biotechnology sector. This recent price movement highlights Ligand Pharmaceuticals' notable position in the market and its performance trajectory over the past year.